Liver abnormalities in drug and substance abusers

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 4, 2013, Pages 577-596

  Pateria, Puraskar ^a   De Boer, Bastiaan ^b,c   MacQuillan, Gerry ^a,d  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Alcohol steatosis; Alcoholic hepatitis; Amphetamine; Cannabis; Cirrhosis; Cocaine; Complementary and alternative medicine; Khat

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; AMPHETAMINE; CATHA EDULIS EXTRACT; CORTICOSTEROID; ETANERCEPT; HERBACEOUS AGENT; INFLIXIMAB; NALTREXONE; PARACETAMOL; PENTOXIFYLLINE; RETINOL;

ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ALTERNATIVE MEDICINE; ARTICLE; CANNABIS ADDICTION; CLINICAL FEATURE; COCAINE DEPENDENCE; DISEASE SEVERITY; DRUG ABUSE; DRUG TOXICITY; HISTOPATHOLOGY; HYPERTENSION; HYPERTHERMIA; LABORATORY TEST; LILLE SCORE; LIVER BIOPSY; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PATHOGENESIS; PHYSICAL EXAMINATION; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; SEDATION; SUBSTANCE ABUSE; ULTRASOUND;

EID: 84885181612     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.08.001     Document Type: Review

References (100)

1. Global status report on alcohol and health. Geneva, Switzerland: World Health Organization; 2011. p. 4-7
2. McClain C, Barve S, Joshi-Barve S, Song Z, Deaciuc I, Chen T, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005;29:180S-8S (Pubitemid 43194348)
3. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006;65:278-90 (Pubitemid 46323842)
4. Deleuran T, Gronb?k H, Vilstrup H, Jepsen P. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. Aliment Pharmacol Ther 2012;35:1336-42
5. Singh DK, Rastogi A, Sakhuja P, Gondal R, Sarin SK. Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients. Indian J Pathol Microbiol 2010;53: 408-13
6. Moussavian SN, Becker RC, Piepmeyer JL, Mezey E, Bozian RC. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig Dis Sci 1985;30:211-4 (Pubitemid 15137009)
7. Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2006;38:485-9 (Pubitemid 44356237)
8. Borra RJ, Salo S, Dean K, Lautamaki R, Nuutila P, Komu M, et al. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Radiology 2009;250:130-6
9. Savolainen VT, Liesto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res 1993;17:1112-7 (Pubitemid 24000535)
10. Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004;24:233-47 (Pubitemid 39167682)
11. Sass DA, Shaikh OS. Alcoholic hepatitis. Clin Liver Dis 2006;10:219-37[vii] (Pubitemid 46110782)
12. Uchida T, Kao H, Quispe-Sjogren M, Peters RL. Alcoholic foamy degeneration - a pattern of acute alcoholic injury of the liver. Gastroenterology 1983;84:683-92 (Pubitemid 13152612)
13. Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-9 (Pubitemid 8372264)
14. Mathurin P, Mendenhall CL, Carithers Jr RL, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-7 (Pubitemid 34407335)
15. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (Baltimore, Md) 2005;41:353-8 (Pubitemid 40165379)
16. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700-6
17. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology (Baltimore, Md) 2007;45:1348-54 (Pubitemid 46918318)
18. Senanayake SM, Niriella MA, Weerasinghe SK, Kasturiratne A, de Alwis JP, de Silva AP, et al. Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes 2012;5:663
19. Saitz R, Palfai TP, Cheng DM, Horton NJ, Freedner N, Dukes K, et al. Brief intervention for medical inpatients with unhealthy alcohol use: a randomized, controlled trial. Ann Intern Med 2007;146:167-76 (Pubitemid 351650629)
20. McCullough AJ, O?Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022-36 (Pubitemid 29076847)
21. O?Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology (Baltimore, Md) 2010;51:307-28
22. Mathurin P, O?Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255-60
23. Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365:1781-9
24. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;37:845-54
25. Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012;57:1664-71
26. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology (Baltimore, Md) 2004;39:1390-7 (Pubitemid 38569061)
27. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953-60
28. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758-69
29. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790-800
30. Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo Y-F. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology (Baltimore, Md) 2012;55: 1398-405
31. Tandon P, Goodman KJ, Ma MM, Wong WW, Mason AL, Meeberg G, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009;104:1700-6
32. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology (Baltimore, Md) 2002;35:635-8 (Pubitemid 34183969)
33. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish populationbased cohort study. Hepatology (Baltimore, Md) 2010;51:1675-82
34. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol: the Official Clinical Practice Journal of the American Gastroenterological Association 2009;7:689-95
35. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006;101:547-55 (Pubitemid 43340931)
36. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology (Baltimore, Md) 2009;49:97-105
37. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73 (Pubitemid 41368177)
38. Ito K, Mitchell DG, Hann HW, Kim Y, Fujita T, Okazaki H, et al. Viral-induced cirrhosis: grading of severity using MR imaging. AJR Am J Roentgenol 1999;173:591-6 (Pubitemid 29395273)
39. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology (Baltimore, Md) 2009;49:1017-44
40. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
41. Kamath PS, Wiesner RH, Malinchoc M, KremersW, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology (Baltimore, Md) 2001;33:464-70 (Pubitemid 32119037)
42. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int: Official Journal of the International Association for the Study of the Liver 2003;23:45-53 (Pubitemid 37265774)
43. Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003;18:357-73 (Pubitemid 37070234)
44. Burra P, Lucey MR. Liver transplantation in alcoholic patients. Transpl Int: Official Journal of the European Society for Organ Transplantation 2005;18:491-8 (Pubitemid 41726849)
45. Murray KF, Carithers Jr RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology (Baltimore, Md) 2005;41:1407-32 (Pubitemid 40770295)
46. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (Baltimore, Md) 2005;42:1364-72 (Pubitemid 43260039)
47. Myers RP, Shaheen AAM, Li B, Dean S, Quan H. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol: the Official Clinical Practice Journal of the American Gastroenterological Association 2008;6:918-25
48. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology (Baltimore, Md) 2002;35:876-82 (Pubitemid 34258382)
49. Waring WS, Stephen AF, Malkowska AM, Robinson OD. Acute acetaminophen overdose is associated with dosedependent hypokalaemia: a prospective study of 331 patients. Basic Clin Pharmacol Toxicol 2008;102:325-8 (Pubitemid 351287566)
50. Singer AJ, Carracio TR, Mofenson HC. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 1995;26:49-53
51. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43:342-9
52. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol: JASN 1995;6:48-53
53. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001;31:55-138 (Pubitemid 32157805)
54. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975;55:871-6
55. Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. J Emerg Med 2006;30:1-5 (Pubitemid 43129870)
56. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev (Online) 2006. CD003328
57. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (Clinical Research Ed) 1991;303:1026-9
58. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988;319:1557-62 (Pubitemid 19003420)
59. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979;2:1097-100 (Pubitemid 10249121)
60. O?Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45 (Pubitemid 19192181)
61. Craig DG, Ford AC, Hayes PC, Simpson KJ. Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment Pharmacol Ther 2010;31:1064-76
62. MacQuillan GC, Seyam MS, Nightingale P, Neuberger JM, Murphy N. Blood lactate but not serum phosphate levels can predict patient outcome in fulminant hepatic failure. Liver Transpl 2005;11:1073-9 (Pubitemid 41341756)
63. World drug report 2012. Austria: United Nations Office on Drugs and Crime (UNODC); 2012
64. Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 2001;64:319-27 (Pubitemid 32973875)
65. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006;67:247-57 (Pubitemid 43357471)
66. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (Baltimore, Md) 2005;42:63-71 (Pubitemid 40911312)
67. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012;169:805-12
68. Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res 2011;186:356-61
69. Bao YP, Liu ZM, Lian Z, Li JH, Zhang RM, Zhang CB, et al. Prevalence and correlates of HIV and HCV infection among amphetamine-type stimulant users in 6 provinces in China. J Acquir Immune Defic Syndr (1999) 2012;60:438-46
70. Maurer HH. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit 2010;32:544-9
71. Greene SL, Dargan PI, O?Connor N, Jones AL, Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine (?ecstasy?). Am J Emerg Med 2003;21:121-4
72. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med: Official Journal of the Society for Academic Emergency Medicine 2005;12:1167-72 (Pubitemid 41683126)
73. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am 2005;89:1277-96 (Pubitemid 41446571)
74. McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 2008;117:1897-907 (Pubitemid 351507480)
75. Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol 2001;43:99-102 (Pubitemid 32230289)
76. Kelty E, Thomson K, Carlstein S, Sinclair R, Hulse G. A retrospective assessment of the use of naltrexone implants for the treatment of problematic amphetamine use. Am J Addict/Am Acad Psychiatr Alcohol Addict 2013;22:1-6
77. Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology (Baltimore, Md) 2007;45:111-7 (Pubitemid 46144370)
78. Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001;64:233-41 (Pubitemid 32816966)
79. Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry 2007;64:1313-20 (Pubitemid 350074829)
80. Silva MO, Roth D, Reddy KR, Fernandez JA, Albores-Saavedra J, Schiff ER. Hepatic dysfunction accompanying acute cocaine intoxication. J Hepatol 1991;12:312-5
81. Kothur R, Marsh F, Posner G. Liver function tests in nonparenteral cocaine users. Arch Intern Med 1991;151:1126-8
82. Sharma R, Organ Jr CH, Hirvela ER, Henderson VJ. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997;174:629-32. [discussion 32-33]
83. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2004;10:1018-23 (Pubitemid 39232756)
84. Bruce-Chwatt RM. Intoxication with Qaat, Catha edulis L. J Forensic Leg Med 2010;17:232-5
85. Stuyt RJL, Willems SM, Wagtmans MJ, van Hoek B. Chewing khat and chronic liver disease. Liver Int 2011;31:434-6
86. Chapman MH, Kajihara M, Borges G, O?Beirne J, Patch D, Dhillon AP, et al. Severe, acute liver injury and khat leaves. N Engl J Med 2010;362:1642-4
87. Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001;135:344-51 (Pubitemid 32823241)
88. Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991;100:1701-9
89. Lam HS, Chow CM, Poon WT, Lai CK, Chan KC, Yeung WL, et al. Risk of vitamin A toxicity from candy-like chewable vitamin supplements for children. Pediatrics 2006;118:820-4 (Pubitemid 46085448)
90. Ukleja A, Scolapio JS, McConnell JP, Spivey JR, Dickson RC, Nguyen JH, et al. Nutritional assessment of serum and hepatic vitamin A levels in patients with cirrhosis. JPEN J Parenter Enteral Nutr 2002;26:184-8 (Pubitemid 34429484)
91. Kowalski TE, Falestiny M, Furth E, Malet PF. Vitamin A hepatotoxicity: a cautionary note regarding 25,000 IU supplements. Am J Med 1994;97:523-8 (Pubitemid 24370883)
92. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003;18:451-71 (Pubitemid 37152286)
93. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol: the Official Clinical Practice Journal of the American Gastroenterological Association 2007;5:408-16 (Pubitemid 46575355)
94. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58:71-80 (Pubitemid 38901470)
95. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145-55 (Pubitemid 34496468)
96. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007;25:1135-51 (Pubitemid 46650295)
97. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010;32:3-13
98. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9 (Pubitemid 43247143)
99. Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56:1405-9 (Pubitemid 32455310)
100. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54 (Pubitemid 35440240)